Compare GLPI & CYTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GLPI | CYTK |
|---|---|---|
| Founded | 2013 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.2B | 10.7B |
| IPO Year | 2013 | 2004 |
| Metric | GLPI | CYTK |
|---|---|---|
| Price | $43.79 | $81.60 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 19 |
| Target Price | $51.95 | ★ $89.26 |
| AVG Volume (30 Days) | ★ 2.8M | 2.4M |
| Earning Date | 04-23-2026 | 05-05-2026 |
| Dividend Yield | ★ 6.50% | N/A |
| EPS Growth | ★ 2.79 | N/A |
| EPS | ★ 0.82 | N/A |
| Revenue | ★ $1,594,752,000.00 | $13,368,000.00 |
| Revenue This Year | $9.17 | $7.37 |
| Revenue Next Year | $5.40 | $310.19 |
| P/E Ratio | $52.65 | ★ N/A |
| Revenue Growth | ★ 4.13 | N/A |
| 52 Week Low | $41.17 | $32.89 |
| 52 Week High | $49.95 | $88.31 |
| Indicator | GLPI | CYTK |
|---|---|---|
| Relative Strength Index (RSI) | 41.51 | 53.33 |
| Support Level | $42.45 | $59.07 |
| Resistance Level | $43.90 | $88.31 |
| Average True Range (ATR) | 0.86 | 2.94 |
| MACD | -0.10 | -0.21 |
| Stochastic Oscillator | 33.48 | 33.67 |
Gaming and Leisure Properties Inc, or GLP, is a self-administered and self-managed Pennsylvania real estate investment trust (REIT). It is engaged in acquiring, financing, and owning real estate property to be leased to gaming operators in triple-net lease arrangements. The company also extends loans that produce fixed or variable returns, which may convert into leased rent upon project completion or stabilization. Its portfolio consists of gaming and related facilities and amenities such as Ameristar Black Hawk, Bally's Casino, Argosy Casino Alton, Bally's Chicago, Hollywood Casino Aurora, and others located across different states in the United States.
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary disease. The company's product, named as MYQORZO, is an allosteric and reversible inhibitor of cardiac myosin motor activity. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.